J&J Procrit Will Rely On New Indications, DTC To Compete With Amgen NESP
Executive Summary
Johnson & Johnson is focusing on consumer education and line extensions to position Procrit for impending competition from Amgen's NESP.
You may also be interested in...
J&J Ultracet Combo Product Labeling Cites Faster Pain Action Than Ultram
Johnson & Johnson's Ultracet delivers a faster onset of action than Ultram (tramadol) alone, labeling for the combination tramadol/acetaminophen drug notes.
J&J Ultracet Combo Product Labeling Cites Faster Pain Action Than Ultram
Johnson & Johnson's Ultracet delivers a faster onset of action than Ultram (tramadol) alone, labeling for the combination tramadol/acetaminophen drug notes.
Amgen Working With Payors To Identify NESP Patients At Primary Care Level
Amgen is working with payors to identify chronic renal insufficiency patients in the primary care market who may be candidates for therapy with the Epogen successor product Aranesp, the company told securities analysts in New York City Nov. 8.